1 / 13

InBio Ltd . _ _______________ ______________ _____

InBio Ltd . _ _______________ ______________ _____. Akadeemia tee 21 • Tallinn • 12680 E s tonia • www.inbio.ee • e -mail: info@inbio.ee • Reg.nr.:10565826. InBio Ltd. ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS. InBio Ltd . _ _______________ ______________ _____.

dominic-nixon
Download Presentation

InBio Ltd . _ _______________ ______________ _____

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. InBio Ltd.___________________________________ Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: info@inbio.ee • Reg.nr.:10565826 InBio Ltd. ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS

  2. InBio Ltd.___________________________________ Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: info@inbio.ee • Reg.nr.:10565826 Facts on InBio • Established in Tallinn, 1999 • General business idea: to develop neweffective and selective skin cancertherapeutics and diagnostics. • The company was initiated by a group of scientists of National Institute of Chemical Physics and Biophysics and KarolinskaInstitute, Sweden

  3. InBio Ltd.___________________________________ 1999 2000 2001 Turnover 10000 225000 190000 Profit beforetaxes -2000 19000 8000 Equity 3300 3300 3300 Employees 2 4 7 Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: info@inbio.ee • Reg.nr.:10565826 Financial results (EUR):

  4. InBio Ltd.___________________________________ Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: info@inbio.ee • Reg.nr.:10565826 Background for product development • Cancer is the second most common cause of death in the developed world • The limits of usefulness are being approached for conventional therapies and further advances will require principally new approaches • The foreseen products of our company areprototypes of new anti-cancer drugs that are characterised by: • -high degree of selectivity • -efficient delivery

  5. InBio Ltd.___________________________________ Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: info@inbio.ee • Reg.nr.:10565826 What is antibody? • Antibodies are made by a class of white blood cells • They are naturally present in the blood • Biological function is to perform defence functions • Each antigen causes the formation of a specific antibody • Recombinant DNA technology allows the engineer antibodies • It is possible to produce complete antibodiesin cell culture systems.

  6. InBio Ltd.___________________________________ Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: info@inbio.ee • Reg.nr.:10565826 Reasons to use antibodies in drug development • Can be rationally designed and easily made • Can be engineered to add fragmenmts that enhance their therapeutic potential • Have no intrinsic toxicity as based on the natural molecules • Monoclonal antibodies (mAbs)will not fail at the drug safety testing (phase I clinical trial stages) • Technology is now advanced enough for therapeutic applications of mAbs

  7. InBio Ltd.___________________________________ Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: info@inbio.ee • Reg.nr.:10565826 What is new in our technology ? • Our technology combines two different platforms: • Monoclonal antibodies against cancer-specific antigens • Modification of antibody sequence to make these mAbs membrane permeable • Such approach helps to utilise intracellular cancer-specific targets that can not be usually reached • Focus on skin cancer, first targets are GLI proteins

  8. InBio Ltd.___________________________________ Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: info@inbio.ee • Reg.nr.:10565826 What are GLI proteins? • GLI proteins are gene switches • GLI proteins are involved in development and lead cells to divide • Abnormal activation of GLI proteins lead to cancer • GLI proteins represent an attractive target for anticancer drug development

  9. InBio Ltd.___________________________________ Gene switch turned on Cancer develops Cancer development inhibited Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: info@inbio.ee • Reg.nr.:10565826

  10. InBio Ltd.___________________________________ Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: info@inbio.ee • Reg.nr.:10565826 Cell penetrating peptides (CPPs) • Family of peptides capable to penetrate cellular membranes • We can transport the following molecules into cells using CPP technology: • -other peptides • -nucleic acids • -proteins e.g. antibodies

  11. InBio Ltd.___________________________________ • World antibody market: • Currently more than 200 monoclonal antibodies are indevelopment • Targeted disorders include cancer, heart disease, infectious diseases and autoimmunediseases • Market is still in its inception stage, • Market size estimated at nearly $2.8 billion in 1999, • Market forecast growth toalmost $9.8 billion in 2004. • Expected therapeutic antibodyaverage annual growth rate is projected at 21,8% • Diagnostic/therapeutic antibody AAGR will grow at fast nearly 50% rate • Main Target Markets for InBio: • Scandinavian Market • U.S. market Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: info@inbio.ee • Reg.nr.:10565826

  12. InBio Ltd.___________________________________ Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: info@inbio.ee • Reg.nr.:10565826 • Timing and positioning • Antibodybased drugsare in the position of significant commercial growth • InBio enters the market at the moment when all developers seek for new approaches • InBio has new technology to make antibodies more effective • InBio has involved outstanding specialists from all fields that are required to accomplish our business plan

  13. InBio Ltd.___________________________________ Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: info@inbio.ee • Reg.nr.:10565826 • Benefits for the investor: Will invest in profitable business at evolving market Will invest in area that is significantly improving the well-being of the mankind Will get possession rights of a unique know-how and new technologies that will realise in new type of therapeutic and diagnostic tools

More Related